IL247321B - uti chimeric proteins - Google Patents
uti chimeric proteinsInfo
- Publication number
- IL247321B IL247321B IL247321A IL24732116A IL247321B IL 247321 B IL247321 B IL 247321B IL 247321 A IL247321 A IL 247321A IL 24732116 A IL24732116 A IL 24732116A IL 247321 B IL247321 B IL 247321B
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- uti fusion
- uti
- proteins
- fusion
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943617P | 2014-02-24 | 2014-02-24 | |
| PCT/US2015/017152 WO2015127391A1 (en) | 2014-02-24 | 2015-02-23 | Uti fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL247321A0 IL247321A0 (en) | 2016-09-29 |
| IL247321B true IL247321B (en) | 2020-06-30 |
Family
ID=52629709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL247321A IL247321B (en) | 2014-02-24 | 2016-08-17 | uti chimeric proteins |
Country Status (38)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20196970B (en) * | 2014-02-24 | 2019-04-25 | Gmbh Takeda | Uti fusion proteins |
| AU2018281306B2 (en) * | 2017-06-07 | 2025-04-17 | Spark Therapeutics, Inc. | Enhancing agents for improved cell transfection and/or rAAV vector production |
| WO2020106881A1 (en) * | 2018-11-20 | 2020-05-28 | Diamedica Inc. | Modified ulinastatin polypeptides |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2021178843A1 (en) * | 2020-03-05 | 2021-09-10 | DiaMedica USA Inc. | Ulinastatin polypeptides |
| CN117015390A (zh) * | 2021-01-29 | 2023-11-07 | 代阿麦迪卡美国股份有限公司 | 用于治疗疾病的乌司他丁多肽 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| DE59007737D1 (de) * | 1989-05-13 | 1995-01-05 | Bayer Ag | Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel. |
| EP0486001A1 (en) | 1990-11-13 | 1992-05-20 | Mochida Pharmaceutical Co., Ltd. | Recombinant urinary trypsin inhibitor fragments and drug composition |
| JP2769083B2 (ja) | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
| IL126115A (en) | 1996-03-11 | 2007-03-08 | Aerovance Inc | Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations |
| DE19725014A1 (de) | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
| NZ550225A (en) * | 2004-03-30 | 2010-11-26 | Glaxo Group Ltd | Immunoglobulins that bind oncostatin and inhibit or block interaction between hOSM and pg130 |
| CA2578613A1 (en) * | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| JP4067557B2 (ja) * | 2005-06-03 | 2008-03-26 | 持田製薬株式会社 | 抗ｃｄ１４抗体融合蛋白質 |
| WO2007079096A2 (en) | 2005-12-29 | 2007-07-12 | Dyax Corp. | Protease inhibition |
| HUE033438T2 (en) * | 2008-09-26 | 2017-11-28 | Ucb Biopharma Sprl | Biological products |
| CN102580085B (zh) * | 2008-10-13 | 2013-09-18 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗脓毒症药物中的应用 |
| CN101721699B (zh) * | 2008-10-13 | 2012-11-07 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
| CA2760674A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| JP5705242B2 (ja) * | 2010-02-19 | 2015-04-22 | ゼンコア インコーポレイテッド | 新規ｃｔｌａ４−ｉｇ免疫アドヘシン |
| CA2834626A1 (en) * | 2011-04-29 | 2012-11-01 | University Of Washington | Therapeutic nuclease compositions and methods |
| US8619331B2 (en) | 2011-07-19 | 2013-12-31 | Xerox Corporation | Simulated paper texture using clear toner and glossmark on texture-less stock |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| BR112014026162A2 (pt) * | 2012-04-23 | 2017-10-03 | Nrl Pharma Inc | Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma |
| CN103044554B (zh) * | 2012-05-14 | 2014-08-27 | 旭华（上海）生物研发中心有限公司 | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 |
| JP2013253079A (ja) * | 2012-05-14 | 2013-12-19 | Xuhua (Shanghai) Biological Research & Development Center Co Ltd | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 |
| GEP20196970B (en) * | 2014-02-24 | 2019-04-25 | Gmbh Takeda | Uti fusion proteins |
-
2015
- 2015-02-23 GE GEAP201514277A patent/GEP20196970B/en unknown
- 2015-02-23 SG SG10201708400QA patent/SG10201708400QA/en unknown
- 2015-02-23 NZ NZ760008A patent/NZ760008A/en unknown
- 2015-02-23 EA EA202091567A patent/EA202091567A1/ru unknown
- 2015-02-23 UA UAA201609101A patent/UA118866C2/uk unknown
- 2015-02-23 PH PH1/2016/501629A patent/PH12016501629B1/en unknown
- 2015-02-23 AU AU2015218704A patent/AU2015218704B2/en active Active
- 2015-02-23 CA CA2939639A patent/CA2939639C/en active Active
- 2015-02-23 CA CA3178241A patent/CA3178241A1/en active Pending
- 2015-02-23 WO PCT/US2015/017152 patent/WO2015127391A1/en not_active Ceased
- 2015-02-23 EP EP18192690.8A patent/EP3443978A1/en not_active Withdrawn
- 2015-02-23 EA EA201691702A patent/EA037256B1/ru unknown
- 2015-02-23 HR HRP20182029TT patent/HRP20182029T1/hr unknown
- 2015-02-23 KR KR1020227037377A patent/KR102722304B1/ko active Active
- 2015-02-23 GE GEAP201814277A patent/GEAP201814277A/en unknown
- 2015-02-23 EP EP15708411.2A patent/EP3110434B1/en active Active
- 2015-02-23 LT LTEP15708411.2T patent/LT3110434T/lt unknown
- 2015-02-23 RS RS20181514A patent/RS58285B1/sr unknown
- 2015-02-23 BR BR112016019390-3A patent/BR112016019390B1/pt active IP Right Grant
- 2015-02-23 CN CN201580014645.3A patent/CN106232135B/zh active Active
- 2015-02-23 NZ NZ724196A patent/NZ724196A/en unknown
- 2015-02-23 DK DK15708411.2T patent/DK3110434T3/en active
- 2015-02-23 SI SI201530516T patent/SI3110434T1/sl unknown
- 2015-02-23 MX MX2020000537A patent/MX384070B/es unknown
- 2015-02-23 PE PE2016001522A patent/PE20170257A1/es unknown
- 2015-02-23 MY MYPI2016703046A patent/MY178774A/en unknown
- 2015-02-23 SM SM20180674T patent/SMT201800674T1/it unknown
- 2015-02-23 SG SG11201606691QA patent/SG11201606691QA/en unknown
- 2015-02-23 ES ES15708411T patent/ES2700149T3/es active Active
- 2015-02-23 NZ NZ760789A patent/NZ760789A/en unknown
- 2015-02-23 KR KR1020247035230A patent/KR20240155987A/ko active Pending
- 2015-02-23 CR CR20160444A patent/CR20160444A/es unknown
- 2015-02-23 MX MX2016010950A patent/MX2016010950A/es active IP Right Grant
- 2015-02-23 PT PT15708411T patent/PT3110434T/pt unknown
- 2015-02-23 PL PL15708411T patent/PL3110434T3/pl unknown
- 2015-02-23 JP JP2016553562A patent/JP6574431B2/ja active Active
- 2015-02-23 KR KR1020167026429A patent/KR102461210B1/ko active Active
- 2015-02-23 CN CN201910282497.3A patent/CN110092837B/zh active Active
- 2015-02-23 US US15/120,956 patent/US9856310B2/en active Active
- 2015-02-23 MA MA39347A patent/MA39347B2/fr unknown
- 2015-08-20 AR ARP150102677A patent/AR101597A1/es unknown
- 2015-08-20 JO JOP/2015/0200A patent/JO3729B1/ar active
- 2015-08-21 TW TW104127393A patent/TWI694084B/zh active
-
2016
- 2016-08-10 DO DO2016000202A patent/DOP2016000202A/es unknown
- 2016-08-17 IL IL247321A patent/IL247321B/en active IP Right Grant
- 2016-08-23 MX MX2019013124A patent/MX2019013124A/es unknown
- 2016-08-23 MX MX2024000004A patent/MX2024000004A/es unknown
- 2016-08-24 CL CL2016002136A patent/CL2016002136A1/es unknown
- 2016-09-13 ZA ZA2016/06327A patent/ZA201606327B/en unknown
- 2016-09-23 EC ECIEPI201676535A patent/ECSP16076535A/es unknown
-
2017
- 2017-11-27 US US15/823,398 patent/US10351618B2/en active Active
-
2018
- 2018-12-18 CY CY181101355T patent/CY1120997T1/el unknown
-
2019
- 2019-02-15 US US16/277,606 patent/US20200040062A1/en not_active Abandoned
- 2019-06-11 JP JP2019109054A patent/JP6938565B2/ja active Active
- 2019-06-25 AU AU2019204448A patent/AU2019204448B2/en active Active
-
2021
- 2021-06-03 US US17/337,922 patent/US20220127334A1/en not_active Abandoned
- 2021-08-31 AU AU2021225156A patent/AU2021225156B2/en active Active
- 2021-09-01 JP JP2021142544A patent/JP2022002513A/ja active Pending
-
2023
- 2023-02-16 AU AU2023200875A patent/AU2023200875A1/en not_active Abandoned
- 2023-06-30 JP JP2023108024A patent/JP2023123763A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254965A0 (en) | fusion proteins | |
| ZA201701810B (en) | Sirp-alpha immunoglobulin fusion proteins | |
| GB201509413D0 (en) | Fusion protein | |
| IL246355A0 (en) | p97–ids fused proteins | |
| GB201504691D0 (en) | Fusion protein | |
| ZA201606327B (en) | Uti fusion proteins | |
| HUE057808T2 (hu) | Fehérje visszanyerés | |
| IL246348A0 (en) | p97 fusion proteins | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| ZA201801394B (en) | Fusion protein | |
| GB201602850D0 (en) | Fusion proteins | |
| GB201617799D0 (en) | Fusion polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide | |
| GB201412797D0 (en) | Proteins | |
| GB201412646D0 (en) | Proteins | |
| GB201412648D0 (en) | Proteins | |
| GB201412649D0 (en) | Proteins | |
| GB201406894D0 (en) | Proteins | |
| GB201405952D0 (en) | Proteins | |
| GB201405955D0 (en) | Proteins | |
| GB201403912D0 (en) | Proteins | |
| GB201403913D0 (en) | Proteins | |
| GB201403915D0 (en) | Proteins | |
| GB201403914D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |